LEADER 01011nam0-22003251i-450- 001 990005588640403321 005 20110928154504.0 010 $a3716500291 035 $a000558864 035 $aFED01000558864 035 $a(Aleph)000558864FED01 035 $a000558864 100 $a19990604d1974----km-y0itay50------ba 101 0 $ager 105 $ay-------001yy 200 1 $a<>Kunstliteratur des Klassizismus und der Romantik in England$fJohannes Dobai 210 $aBern$cBenteli$dc1974 215 $a3 v.$d25 cm 610 0 $aNeoclassicismo$aGran Bretagna 676 $a709.0341 700 1$aDobai,$bJohannes$0215548 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990005588640403321 952 $a709.0341 DOB 1 (1)$bST. ARTE 12195$fFLFBC 952 $a709.0341 DOB 1 (2)$bST. ARTE 12195$fFLFBC 952 $a709.0341 DOB 1 (3)$bST. ARTE 12195$fFLFBC 959 $aFLFBC 996 $aKunstliteratur des Klassizismus und der Romantik in England$9608435 997 $aUNINA LEADER 02896nam 22006014a 450 001 9910144118603321 005 20170815120251.0 010 $a1-118-15896-2 010 $a1-281-93930-7 010 $a9786611939304 010 $a0-470-43467-8 010 $a0-470-43465-1 035 $a(CKB)1000000000555496 035 $a(EBL)380459 035 $a(OCoLC)476208766 035 $a(SSID)ssj0000141596 035 $a(PQKBManifestationID)11148633 035 $a(PQKBTitleCode)TC0000141596 035 $a(PQKBWorkID)10090702 035 $a(PQKB)10242657 035 $a(MiAaPQ)EBC380459 035 $a(EXLCZ)991000000000555496 100 $a20080728d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aDrug truths$b[electronic resource] $edispelling the myths about pharma R&D /$fJohn L. LaMattina 210 $aHoboken, N.J. $cJohn Wiley & Sons$dc2009 215 $a1 online resource (156 p.) 300 $aDescription based upon print version of record. 311 $a0-470-39318-1 320 $aIncludes bibliographical references (p. 124-132) and index. 327 $aCholesterol drugs are unnecessary -- Industry is more interested in 'me-too' drugs than in innovation -- It takes industry too long to discover new drugs -- Drugs are discovered by academia -- New medicines add costs but little benefit -- Big pharma has failed and should learn from biotech success -- The industry invents diseases -- New drugs are less safe than traditional medicines -- Industry spends more on advertising than R&D -- Industry does not care about diseases of the developing world -- Big pharma's day has passed -- Final reflections. 330 $aThis book answers the questions about the process and costs of pharmaceutical R & D in a compelling narrative focused on the discovery and development of important new medicines. It gives an insider's account of the pharmaceutical industry drug discovery process, the very real costs of misperceptions about the industry, the high stakes--both economic and scientific--of developing drugs, the triumphs that come when new compounds reach the market and save lives, and the despair that follows when new compounds fail. In the book, John LaMattina, former president of Pfizer Global Research and Devel 606 $aDrug development$zUnited States 606 $aPharmaceutical industry$zUnited States 606 $aDrugs$xResearch$zUnited States 608 $aElectronic books. 615 0$aDrug development 615 0$aPharmaceutical industry 615 0$aDrugs$xResearch 676 $a338.4761519 676 $a615/.19 700 $aLaMattina$b John L$0963935 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910144118603321 996 $aDrug truths$92232546 997 $aUNINA